- Home
- MGNX vs NUTR Comparison
MGNX vs NUTR Comparison
Compare MGNX & NUTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- NUTR
- Stock Information
- Founded
- MGNX 2000
- NUTR 2013
- Country
- MGNX United States
- NUTR Indonesia
- Employees
- MGNX N/A
- NUTR N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- NUTR
- Sector
- MGNX Health Care
- NUTR
- Exchange
- MGNX Nasdaq
- NUTR Nasdaq
- Market Cap
- MGNX 99.7M
- NUTR 94.1M
- IPO Year
- MGNX 2013
- NUTR 2025
- Fundamental
- Price
- MGNX $1.53
- NUTR $5.40
- Analyst Decision
- MGNX Hold
- NUTR
- Analyst Count
- MGNX 6
- NUTR 0
- Target Price
- MGNX $3.20
- NUTR N/A
- AVG Volume (30 Days)
- MGNX 1.0M
- NUTR 1.1M
- Earning Date
- MGNX 11-04-2025
- NUTR 11-02-2025
- Dividend Yield
- MGNX N/A
- NUTR N/A
- EPS Growth
- MGNX N/A
- NUTR N/A
- EPS
- MGNX N/A
- NUTR 0.00
- Revenue
- MGNX $165,495,000.00
- NUTR $1,743,679.00
- Revenue This Year
- MGNX N/A
- NUTR N/A
- Revenue Next Year
- MGNX N/A
- NUTR N/A
- P/E Ratio
- MGNX N/A
- NUTR $2,384.56
- Revenue Growth
- MGNX 303.47
- NUTR N/A
- 52 Week Low
- MGNX $0.99
- NUTR $3.40
- 52 Week High
- MGNX $5.10
- NUTR $5.63
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- NUTR N/A
- Support Level
- MGNX $1.46
- NUTR N/A
- Resistance Level
- MGNX $1.77
- NUTR N/A
- Average True Range (ATR)
- MGNX 0.15
- NUTR 0.00
- MACD
- MGNX -0.04
- NUTR 0.00
- Stochastic Oscillator
- MGNX 9.21
- NUTR 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About NUTR Nusatrip Incorporated Common Stock
NusaTrip Inc operates as an Online Travel Agent offering Hotel & Flight Tickets, Domestic and International. The Company currently operates in a single reportable operating segment with five different services: Ticketing, Online advertisement, Hotel reservation, Hotel technology platform software, and Ancillary. The group earns revenue through commissions, service fees, and advertising partnerships.